Altered lipidome and antioxidative activity of small, dense HDL in normolipidemic rheumatoid arthritis: Relevance of inflammation

Rosso, Leonardo Adrián Gomez; Lhomme, Marie; Meroño, Tomás; Sorroche, Patricia; Catoggio, Luís J.; Soriano, Enrique R.; Saucedo, Carla; Malah, Verónica; Dauteuille, Carolane; Boero, Laura; Lesnik, Philippe; Robillard, Paul; Chapman, M. John; Brites, Fernando; Kontush, Anatol

doi:10.1016/j.atherosclerosis.2014.09.034

Cited by 49 publications

(34 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, high level of inflammation, such as that observed post-MI, may be required to induce functional alterations in HDL. Indeed, low-grade chronic inflammation, as observed in chronic rheumatoid arthritis, is insufficient to alter HDL function [24]. ApoA-I plays a key role in both the cholesterol efflux and antioxidative activities of HDL, via its interaction with cell membrane proteins, primarily ATP-binding cassette transporter A1 (ABCA1) [21], and via inactivation of lipid hydroperoxides [22], respectively; equally apoA-I may undergo covalent modification upon interaction with both oneand two-electron oxidants [25].…”

Section: Discussionmentioning

confidence: 99%

Defective functionality of small, dense HDL3 subpopulations in ST segment elevation myocardial infarction: Relevance of enrichment in lysophosphatidylcholine, phosphatidic acid and serum amyloid A

Rached

Lhomme

Camont

et al. 2015

Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biolog

Self Cite

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Defective functionality of small, dense HDL3 subpopulations in ST segment elevation myocardial infarction: Relevance of enrichment in lysophosphatidylcholine, phosphatidic acid and serum amyloid A

Rached

Lhomme

Camont

et al. 2015

Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biolog

Self Cite

View full text Add to dashboard Cite

“…Rheumatoid arthritis (RA) affects nearly 1% of the general population and is characterized by a high systemic inflammatory burden, with reduced life expectancy and increased mortality (1). Patients with RA present with a high prevalence of cardiovascular disease (CVD) and a high risk of developing fatal cardiac events, while traditional risk factors do not adequately reflect the increased probability of myocardial infarction, stroke or heart failure development (2–4).…”

Section: Introductionmentioning

confidence: 99%

“…Apart from traditional risk factors, the chronic inflammatory status of these patients is a prime contributor to their increased risk of developing CVD, promoting subtle changes in lipid levels, as well as in the levels of low-density lipoprotein (LDL), high-density lipoprotein (HDL) and triglycerides (TGs) (1,6,8)…”

Section: Introductionmentioning

confidence: 99%

Lipoprotein redox status evaluation as a marker of cardiovascular disease risk in patients with inflammatory disease

Ungurianu

Margină

Grădinaru

et al. 2016

Molecular Medicine Reports

View full text Add to dashboard Cite

Patients with chronic inflammatory disorders (ID) have an increased risk of developing cardiovascular disease, and routinely determined parameters do not reveal the real metabolic status of specific subgroups, such as patients with rheumatoid arthritis (RA). In this study, in order to evaluate state of the art markers for the assessment of cardiometabolic risk, abnormalities in lipoprotein levels in patients with a low-grade inflammatory status [diabetes mellitus (DM) subgroup] and in patients with a high systemic inflammatory burden (RA subgroup) was determined. The study group comprised patients with ID [DM (n=20) and RA (n=20)], with an aged-matched control group (n=17). Patient serum was used to determine routine biochemical parameters and to isolate low-density lipoprotein (LDL) and high-density lipoprotein (HDL). The heparin-citrate method was used for LDL precipitation and the phosphotungstic acid-MgCl2 technique for the isolation of HDL. Further, Amplex Red and advanced oxidation protein product (AOPP) assays were applied to determine lipid peroxides and protein oxidation, respectively, while the levels of serum advanced glycation end products (AGEs) were also determined. Although the differences in the routinely determined lipidemic profile were notable between the DM and RA subgroups, markers of lipid peroxidation and of advanced protein oxidation/glycation did not differ significantly, indicating possible similar oxidative damage of serum lipoproteins. On the whole, as alterations in lipoprotein functionality can occur long before any changes in routinely measured biochemical parameters are observed, more sensitive markers for the assessment of cardiovascular risk are required. As AOPPs, AGEs, oxidized LDL (oxLDL) and especially oxidized HDL (oxHDL) are affected during the early stages of inflammatory disease, and due to their known link to coronary artery disease, it would be wise to include these markers in the routine cardiovascular evaluation of patients with chronic inflammatory disease, such as those with RA.

show abstract

“…For instance, HDLs play a critical role in reverse cholesterol transport, a process that results in the net transfer of cholesterol from peripheral tissues, such as cholesterol loaded macrophages in the arterial wall, to the liver for excretion. 1, 2 HDLs interact with cells in a receptor-mediated fashion, 3 and their natural cargo comprises a variety of lipids, 4 proteins, 5 and microRNAs. 6 These observations motivate the use of HDL and HDL analogs for therapeutic delivery systems.…”

Section: Introductionmentioning

confidence: 99%

High-density lipoproteins for therapeutic delivery systems

2016

View full text Add to dashboard Cite

High-density lipoproteins (HDL) are a class of natural nanostructures found in the blood and are composed of lipids, proteins, and nucleic acids (e.g. microRNA). Their size, which appears to be well-suited for both tissue penetration/retention as well as payload delivery, long circulation half-life, avoidance of endosomal sequestration, and potential low toxicity are all excellent properties to model in a drug delivery vehicle. In this review, we consider high-density lipoproteins for therapeutic delivery systems. First we discuss the structure and function of natural HDL, describing in detail its biogenesis and transformation from immature, discoidal forms, to more mature, spherical forms. Next we consider features of HDL making them suitable vehicles for drug delivery. We then describe the use of natural HDL, discoidal HDL analogs, and spherical HDL analogs to deliver various classes of drugs, including small molecules, lipids, and oligonucleotides. We briefly consider the notion that the drug delivery vehicles themselves are therapeutic, constituting entities that exhibit “theralivery.” Finally, we discuss challenges and future directions in the field.

show abstract

Altered lipidome and antioxidative activity of small, dense HDL in normolipidemic rheumatoid arthritis: Relevance of inflammation

Cited by 49 publications

References 50 publications

Defective functionality of small, dense HDL3 subpopulations in ST segment elevation myocardial infarction: Relevance of enrichment in lysophosphatidylcholine, phosphatidic acid and serum amyloid A

Defective functionality of small, dense HDL3 subpopulations in ST segment elevation myocardial infarction: Relevance of enrichment in lysophosphatidylcholine, phosphatidic acid and serum amyloid A

Lipoprotein redox status evaluation as a marker of cardiovascular disease risk in patients with inflammatory disease

High-density lipoproteins for therapeutic delivery systems

Contact Info

Product

Resources

About